Kim Yonggoo, Park Joonhong, Kim Myungshin
Department of Laboratory Medicine, Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Blood Res. 2017 Jun;52(2):84-94. doi: 10.5045/br.2017.52.2.84. Epub 2017 Jun 22.
Inherited hemolytic anemias (IHAs) are genetic diseases that present with anemia due to the increased destruction of circulating abnormal RBCs. The RBC abnormalities are classified into the three major disorders of membranopathies, hemoglobinopathies, and enzymopathies. Traditional diagnosis of IHA has been performed via a step-wise process combining clinical and laboratory findings. Nowadays, the etiology of IHA accounts for germline mutations of the responsible genes coding for the structural components of RBCs. Recent advances in molecular technologies, including next-generation sequencing, inspire us to apply these technologies as a first-line approach for the identification of potential mutations and to determine the novel causative genes in patients with IHAs. We herein review the concept and strategy for the genetic diagnosis of IHAs and provide an overview of the preparations for clinical applications of the new molecular technologies.
遗传性溶血性贫血(IHA)是一类遗传性疾病,由于循环中异常红细胞的破坏增加而导致贫血。红细胞异常可分为膜病、血红蛋白病和酶病这三大类疾病。IHA的传统诊断是通过结合临床和实验室检查结果的逐步过程来进行的。如今,IHA的病因是编码红细胞结构成分的相关基因的种系突变。包括下一代测序在内的分子技术的最新进展促使我们将这些技术作为一线方法来识别潜在突变,并确定IHA患者的新致病基因。我们在此回顾IHA基因诊断的概念和策略,并概述新分子技术临床应用的准备工作。